Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Cyclacel has achieved a key milestone in ready to start Phase 2 on the concept stage with important capitalists anticipated in 2024 and a strong competitive profile in its therapeutic class |
| We are very encouraged that these are the best patients for our response |
| We are pleased to report on the progress of fadraciclib, our CDK2/9 inhibitor, or fadra for short |
| In the 140-101 dose escalation study of plogo, we have enrolled 15 patients with good tolerability so far |
| We are also encouraged by Phase 1 anti-cancer activity observed in our T-cell lymphoma patients, including PRs in two out of three patients |
| An illustration of this is we were excited to see shrinkage of 22% in the sum of all target lesions of the one cycle of oral fadraciclib in a squamous non-small cell lung cancer patient with CDKN2B deletion refractory to standard of care chemotherapy and immunotherapy |
| He has extensive clinical and product development experience, which will be instrumental in guiding our team to deliver key value inflection milestones |
| We estimate that approximately eight sites will take part in the Phase 2 and have completed several site initiation visits, so we can quickly start enrollment and deliver results by the second half of 2024 |
| Ahu Demir Good afternoon |
| We believe that there is great unmet medical need and industry interest in the cancer patient populations identified by these abnormalities, which are closely located on chromosome 9 and are often co-deleted |
| We are delighted to be joined on today's call by Dr |
| Ahu Demir Thank you |
| Thank you |
| Thank you |
| Statement |
|---|
| These patient groups are associated with a high unmet medical need and often have poor clinical outcomes |
| We have also observed CDKN2A or B alterations, including loss of function in multiple pre-treated Phase 1 patients with various cancers, including gynecological, hepatobiliary, lung, and pancreatic who have benefited from fadraciclib monotherapy |
| That's the reason we just had to pause the program in favor of improving our [pharmacokinetics] (ph) |
| R&D expenses related to plogo were $0.7 million and $5 million for the three months and year ended December 31, 2023, as compared to $1.3 million and $5.5 million for the same period in 2022 due to decrease in manufacturing and other non-clinical expenditures |
| General and administrative expenses for the three months and year ended December 31, 2023 were $1.9 million and $6.7 million, compared to $2.1 and $7.4 million in the same period of the previous year due to a decrease in professional fees |
| So two questions related to that |
Please consider a small donation if you think this website provides you with relevant information